Cargando…

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients

Chronic hepatitis C (CHC) is strongly associated with risks of cardiovascular diseases. The impact of direct acting antiviral (DAA) therapy on central blood pressure remains unclear. This investigation evaluates changes in central blood pressure following DAA therapy. One hundred and two DAA-treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Pin-Nan, Chen, Ju-Yi, Chiu, Yen-Cheng, Chiu, Hung-Chih, Tsai, Liang-Miin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363767/ https://www.ncbi.nlm.nih.gov/pubmed/30723238 http://dx.doi.org/10.1038/s41598-018-37829-4

Ejemplares similares

The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program
por: Cheng, Pin-Nan, et al.
Publicado: (2016)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
por: Tajiri, Kazuto, et al.
Publicado: (2023)

Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community
por: Cheng, Pin-Nan, et al.
Publicado: (2018)

Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
por: Yoo, Hae Won, et al.
Publicado: (2022)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
por: Vernuccio, Federica, et al.
Publicado: (2022)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
por: Wu, I-Chin, et al.
Publicado: (2021)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation
por: Emamaullee, Juliet A., et al.
Publicado: (2019)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
por: Kao, Chih-Chin, et al.
Publicado: (2018)

The characteristics of residents with unawareness of hepatitis C virus infection in community
por: Cheng, Pin-Nan, et al.
Publicado: (2018)

Association between Liver Stiffness and Liver-Related Events in HCV-Infected Patients after Successful Treatment with Direct-Acting Antivirals
por: Rodprasert, Napas, et al.
Publicado: (2023)

Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease — a nationwide cohort study
por: Lin, Ming-Shyan, et al.
Publicado: (2017)

Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment
por: Chiu, Shao-Ming, et al.
Publicado: (2020)

24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy
por: Pérez-Is, Laura, et al.
Publicado: (2022)

Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment
por: Tsai, Wei-Chu, et al.
Publicado: (2023)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Tokuchi, Yoshimasa, et al.
Publicado: (2021)

Association of serum leptin levels with central arterial stiffness in coronary artery disease patients
por: Tsai, Jen-Pi, et al.
Publicado: (2016)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Hepatitis B Co-Infection Has Limited Impact on Liver Stiffness Regression in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals
por: Hsu, Cheng-Er, et al.
Publicado: (2022)

Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients
por: Gambato, Martina, et al.
Publicado: (2023)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
por: Dajti, Elton, et al.
Publicado: (2021)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication
por: Nahon, Pierre, et al.
Publicado: (2019)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment
por: Morimoto, Naoki, et al.
Publicado: (2019)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
por: Álvarez, Beatriz, et al.
Publicado: (2020)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis
por: Xia, Huan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_une00dj16ddd0fbvelkd1ovd9g